生长激素轴 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
| 性质 | 取值 | 备注 |
|---|---|---|
| 分子类型 | 合成四十四肽 | GHRH 类似物 |
| N 端修饰 | 反式-3-己烯酰基 | 延缓酶切 |
| 分子量 | 约 5135 Da | 依序列与修饰 |
| 受体靶点 | 垂体 GHRH 受体 | 经 cAMP 通路 |
| 常见同义名 | GHRH(1-44) 类似物 | 文献通用称法 |
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
More than 30 signs and symptoms are variably associated with Marfan syndrome. The most prominent of these affect the skeletal, cardiovascular, and ocular systems, but all fibrous connective tissue throughout the body can be affected.
; if it is equal to zero the chemical reaction is said to be at equilibrium. There exist only limited possible states of energy for electrons, atoms and molecules. These are determined by the rules of quantum mechanics, which require quantization of energy of a bound system. The atoms/molecules in a higher energy state are said to be excited. The molecules/atoms of substance in an excited energy state are often much more reactive; that is, more amenable to chemical reactions. The phase of a substance is invariably determined by its energy and the energy of its surroundings. When the intermolecular forces of a substance are such that the energy of the surroundings is not sufficient to overcome them, it occurs in a more ordered phase like liquid or solid as is the case with water (H2O); a liquid at room temperature because its molecules are bound by hydrogen bonds. Whereas hydrogen sulfide (H2S) is a gas at room temperature and standard pressure, as its molecules are bound by weaker dipole–dipole interactions. The transfer of energy from one chemical substance to another depends on the size of energy quanta emitted from one substance. However, heat energy is often transferred more easily from almost any substance to another because the phonons responsible for vibrational and rotational energy levels in a substance have much less energy than photons invoked for the electronic energy transfer.
== External links == National Isotope Development Center U.S. Government resources for isotopes - production, distribution, and information Isotope Development & Production for Research and Applications (IDPRA) U.S. Department of Energy program sponsoring isotope production and production research and development
Some clinical tests require clinical chemists to process the specimen before testing. Clinical chemists and medical laboratory scientists serve as the interface between the laboratory side and the clinical practice, providing suggestions to physicians on which test panel to order and interpret any irregularities in test results that reflect on the patient's health status and organ system functionality. This allows healthcare providers to make more accurate evaluation of a patient's health and to diagnose disease, predicting the progression of a disease (prognosis), screening, and monitoring the treatment's efficiency in a timely manner. The type of test required dictates what type of sample is used.
Beta blockers are used to treat anxiety disorders including performance anxiety, panic disorder, generalized anxiety disorder, and specific phobias. They are not formally approved for anxiolytic use by the United States Food and Drug Administration. However, many clinical studies have found beta blockers to be effective for anxiety, though the exact mechanism of action is unclear. A 2025 systematic review and meta-analysis found widespread prescription of beta blockers, namely propranolol, for the treatment of anxiety disorders, but found no evidence of a beneficial effect relative to placebo or benzodiazepines in people with social phobia or panic disorder. However, the quality of evidence, including both numbers of studies and patients as well as quality and risk of bias of those studies, was limited. Findings were similar in a previous 2016 systematic review and meta-analysis. Beta blockers that have been used to treat anxiety include propranolol, atenolol, pindolol, nadolol, betaxolol, and oxprenolol. It is thought that beta blockers do not directly treat psychological symptoms of anxiety, but can help control physical symptoms such as palpitations, and this may interfere with a positive feedback loop to indirectly reduce psychological anxiety. Highly lipophilic beta blockers like propranolol, which are centrally permeable, and highly hydrophilic beta blockers like atenolol, which are peripherally selective, appear to have similar benefits on performance anxiety, suggesting that their anxiolytic effects are mediated peripherally.
Sources: en.wikipedia.org
== Research == 1999: Preliminary results of early clinical trials with the fully human anti-TNF monoclonal antibody D2E7. 2001, June: Results from ARMADA, a double-blind, placebo-controlled clinical trial involving 271 patients with active rheumatoid arthritis, despite treatment with methotrexate, are announced. Results show that 50% of patients demonstrate a 50% improvement in their American College of Rheumatology (ACR) score. 2002: Broke ground on a new biologics manufacturing facility. 2002: Adalimumab results from five separate trials show that it is effective at reducing signs and symptoms of rheumatoid arthritis, with rapid onset of action and sustained efficacy. Adalimumab was safe and effective when given alone or in combination with methotrexate (MTX) as a subcutaneous injection. 2002: Humira approved by the US Food and Drug Administration (FDA) for treatment of rheumatoid arthritis. 2003: Humira made available for the treatment of rheumatoid arthritis and continued clinical studies for additional indications. 2005: Humira made available for the treatment of psoriatic arthritis. Exceeded US$1 billion in annual sales for the first time. 2005: Japanese company Eisai submits new drug application to make adalimumab (D2E7) available for the treatment of rheumatoid arthritis in Japan. 2006: Submitted Humira for approval for the treatment of Crohn's disease. Approved for the treatment of ankylosing spondylitis. Exceeded US$2 billion in annual sales. 2007: Humira approved for the treatment of Crohn's disease in the United States.
The Military Religious Freedom Foundation received more than 200 complaints from 50 military installations, and said that such statements are a violation of the Uniform Code of Military Justice (UCMJ) and reflect Secretary Hegseth's leadership. Multiple members of Congress are requesting an investigation into the DoD over the statements alleged to have been made by several military commanders using biblical references and claiming that the president was anointed by Jesus. The members included Rep. Chrissy Houlahan D-PA, the ranking member of the House Armed Services Subcommittee on Military Personnel. A letter they sent to the military Inspector General stated, "If accurate, these outrageous statements—justifying a war based on interpretations of biblical prophecies, and informing troops that they are risking their lives to advance a specific religious vision—raises not only glaring Constitutional concerns, but potential violations of Department of Defense regulations regarding religious neutrality and breaches of professional obligations and standards expected of military leadership." The complaint asks to determine: if military commanders made the statements and if so, where did statements first originate in the chain of command; did the statements violate DoD Instruction 1300.17 on religious freedom; how widespread were the comments within the military; did service members fear retaliation for reporting the comments; what guidance and training exists to ensure compliance with the DoD policy; and what action should be taken against personnel who violated the policy.
The vaginal cuff is the upper portion of the vagina that opens up into the peritoneum and is sutured shut after the removal of the cervix and uterus during a hysterectomy. The vaginal cuff is created by suturing together the edges of the surgical site where the cervix was attached to the vagina. This is accomplished by bringing the edges of the vagina together and suturing them together and to the uterosacral ligaments to prevent prolapse. The peritoneum is also sewn into the newly created vaginal cuff. There may be an advantage to using one method of closure over another. The vaginal cuff has a tendency to partially or completely dehisce or open up. A further complication that can accompany the dehiscence of the vaginal cuff is evisceration or the movement of intestines into the vagina. Some or all of the vaginal cuff can reopen. The risk of vaginal cuff complications is related to the approach to hysterectomy: robotic-assisted total laparoscopic hysterectomy, total laparoscopic hysterectomy, laparoscopic-assisted vaginal hysterectomy, total abdominal hysterectomy, and total vaginal hysterectomy. The vaginal cuff can be stressed by sexual intercourse, chronic constipation, asthma, COPD, and other actions that increase intra-abdominal pressure. This structure is prone to infection, hematoma and other postoperative complications. Factors that are thought to affect wound healing are radiation treatments, age, pelvic organ prolapse, the use of corticosteroids, concurrent malignancy.
COLD-PCR (co-amplification at lower denaturation temperature PCR) is a modified polymerase chain reaction (PCR) protocol that enriches variant alleles from a mixture of wildtype and mutation-containing DNA. The ability to preferentially amplify and identify minority alleles and low-level somatic DNA mutations in the presence of excess wildtype alleles is useful for the detection of mutations. Detection of mutations is important in the case of early cancer detection from tissue biopsies and body fluids such as blood plasma or serum, assessment of residual disease after surgery or chemotherapy, disease staging and molecular profiling for prognosis or tailoring therapy to individual patients, and monitoring of therapy outcome and cancer remission or relapse. Common PCR will amplify both the major (wildtype) and minor (mutant) alleles with the same efficiency, occluding the ability to easily detect the presence of low-level mutations. The capacity to detect a mutation in a mixture of variant/wildtype DNA is valuable because this mixture of variant DNAs can occur when provided with a heterogeneous sample – as is often the case with cancer biopsies. Currently, traditional PCR is used in tandem with a number of different downstream assays for genotyping or the detection of somatic mutations. These can include the use of amplified DNA for RFLP analysis, MALDI-TOF (matrix-assisted laser-desorption–time-of-flight) genotyping, or direct sequencing for detection of mutations by Sanger sequencing or pyrosequencing.
Sources: en.wikipedia.org
If microbial growth is detected, a Gram stain is conducted from the culture bottle to confirm that organisms are present and provide preliminary information about their identity. The blood is then subcultured, meaning it is streaked onto an agar plate to isolate microbial colonies for full identification and antimicrobial susceptibility testing. Because it is essential that bloodstream infections are diagnosed and treated quickly, rapid testing methods have been developed using technologies like polymerase chain reaction and MALDI-TOF MS. Procedures for culturing the blood were published as early as the mid-19th century, but these techniques were labour-intensive and bore little resemblance to contemporary methods. Detection of microbial growth involved visual examination of the culture bottles until automated blood culture systems, which monitor gases produced by microbial metabolism, were introduced in the 1970s. In developed countries, manual blood culture methods have largely been made obsolete by automated systems.
=== Amplifying fluorescent polymer === Amplifying fluorescent polymer (AFP) is a promising new technology and is based on synthesized polymers which bind to explosive molecules and give an amplified signal upon detection. When compounds that are not polymers are utilized for such purpose, the quenching of the fluorescence by the traces of explosives is not detectable. When amplifying fluorescent polymer in thin films absorbs a photon of light, excited state polymers (excitons) are able to migrate along the polymer backbone and between the adjacent polymer films. These sensors were originally made in order to detect trinitrotoluene. In AFP, binding of one TNT molecule results in quenching of fluorescence significantly due to the conjugated structure of the polymers. It has been reported that in practice the polymers result in 100-1000 fold increase of amplification of the quenching response. "During its excited state lifetime, the exciton propagates by a random walk through a finite volume of the polymer film." Once TNT, or any other electron-deficient (i.e., electron accepting) molecule comes in contact with the polymer, a so-called low-energy ‘trap’ forms. "If the exciton migrates to the site of the bound electron-deficient molecule before transitioning back to the ground state, the exciton will be trapped (a non-radioactive process), and no fluorescence will be observed from the excitation event.
Commission A2: Liquefaction and Separation of Gases The work of "Commission A2: Liquefaction and Separation of Gases" reflects worldwide activities in the domain of separation of gases and liquefaction. Apart from the personal involvement of Commission members in various projects, the commission is present at conferences, workshops and seminars: LNG International Exhibition and Conference, GASTECH, Cryogenics, Cryogen Expos, European Cryogenic Course and others. The commission is close to academia, industry and end users of separated and liquefied gases. Commission members work closely with Commission A1 Cryophysics, Cryoengineering and Commission C1 Cryobiology, Cryomedicine and Health Products.
Sources: en.wikipedia.org
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。
作为多肽，它难以通过胃肠道吸收，通常需要注射给药。口服会因消化酶降解而失去活性，因此文献中讨论的都是注射途径。
公开研究多集中在内脏脂肪、体成分分布以及与生长激素轴相关的代谢指标。长期安全性和在普通人群中的适用性尚缺乏一致结论。
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.